Increased PD-L1 expression in both tumor cells and infiltrating myeloid immune cells has been documented in many cancers as a promoter of tumorigenesis and/or the tumor immune escape mechanism, and strategies aimed at blocking PD-1 and CTLA-4 inhibitory signaling are being successfully used in several cancer types [66]. Here, CTLA4 is linked to neoplasm.